Thursday, October 13, 2005
A few current PMP articles
Just a quick rundown of some recent news in the PMP industry:
First up by way of Plantpharma.org;
Dow AgroSciences, Sangamo BioSciences Announce Research and Commercial License Agreement in Plant Agriculture Basically, Dow is licensing technology involving specially designed transcription factors that recognize specific DNA sequences. Transcription factors, for the layperson, are proteins which regulate the transcription and eventual production (translation) of proteins from targeted genes. These TF's will be used to control expression of recombinant protein products. This is an interesting article because it again mentions Dow using technology for " use in plants and plant cell cultures. If you are an adamant reader now full of "common sense" from this blog, you will know that Dow signed a collaboration deal with Chlorogen in September in which the two companies would work to produce recombinant proteins in plant cell cultures. It really looks to me like Dow is making a major investment in plant cell culture technology. Here's another one concerning Dow Agrisciences that came out today(I use Dow and Dow Agrisciences interchangably): SEMBIOSYS COMPLETES ANIMAL VACCINE FEASIBILITY PROGRAM FOR DOW AGROSCIENCES Once again, Dow looks to be really investing in plant pharma and plant made pharmacueticals. To be honest though, I don't know how much research is going on in side the company. And for those of you who are new around here, and even for those who are regulars, here is another good review article concerning plant-made pharmaceuticals. Well, that will about wrap up the serious portion for tonight, hopefully my samples will be done speedvaccing soon (yes I am still in the lab) and I can go home.
|
Dow AgroSciences, Sangamo BioSciences Announce Research and Commercial License Agreement in Plant Agriculture Basically, Dow is licensing technology involving specially designed transcription factors that recognize specific DNA sequences. Transcription factors, for the layperson, are proteins which regulate the transcription and eventual production (translation) of proteins from targeted genes. These TF's will be used to control expression of recombinant protein products. This is an interesting article because it again mentions Dow using technology for " use in plants and plant cell cultures. If you are an adamant reader now full of "common sense" from this blog, you will know that Dow signed a collaboration deal with Chlorogen in September in which the two companies would work to produce recombinant proteins in plant cell cultures. It really looks to me like Dow is making a major investment in plant cell culture technology. Here's another one concerning Dow Agrisciences that came out today(I use Dow and Dow Agrisciences interchangably): SEMBIOSYS COMPLETES ANIMAL VACCINE FEASIBILITY PROGRAM FOR DOW AGROSCIENCES Once again, Dow looks to be really investing in plant pharma and plant made pharmacueticals. To be honest though, I don't know how much research is going on in side the company. And for those of you who are new around here, and even for those who are regulars, here is another good review article concerning plant-made pharmaceuticals. Well, that will about wrap up the serious portion for tonight, hopefully my samples will be done speedvaccing soon (yes I am still in the lab) and I can go home.
